CJC-1295 no DAC & Ipamorelin for Body Recomposition

CJC-1295 no DAC & Ipamorelin for Body Recomposition

Research from the Journal of Clinical Endocrinology & Metabolism found that combining a GHRH analog with a ghrelin mimetic produces GH secretion patterns closer to natural pulsatile release than either compound alone—meaning the CJC-1295 no DAC & Ipamorelin for body recomposition combination isn't just additive, it's synergistic. The GHRH analog extends pulse duration while the ghrelin mimetic increases pulse amplitude, creating a hormonal environment that supports simultaneous fat oxidation and lean tissue preservation in ways single-peptide protocols cannot replicate.

We've worked with researchers across multiple institutions who've studied growth hormone secretagogues for metabolic outcomes. The gap between theoretical mechanism and practical application comes down to dosing precision, injection timing relative to natural GH pulse windows, and understanding what body recomposition actually means at the tissue level—not just scale weight.

What is CJC-1295 no DAC & Ipamorelin for body recomposition?

CJC-1295 no DAC & Ipamorelin for body recomposition is a dual-peptide protocol combining a growth hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue to increase endogenous GH release through complementary pathways. CJC-1295 no DAC binds to GHRH receptors on somatotroph cells in the anterior pituitary, extending the duration of GH pulses, while Ipamorelin selectively activates ghrelin receptors to amplify pulse magnitude without elevating cortisol or prolactin. This combination produces GH secretion patterns that more closely mirror natural pulsatile release than supraphysiological exogenous GH administration.

The reason this specific pairing matters for body recomposition—defined as simultaneous reduction in fat mass and preservation or increase in lean mass—is the temporal profile of GH secretion it creates. Natural GH pulses occur primarily during deep sleep and post-exercise, with peak concentrations lasting 20–30 minutes before clearance. CJC-1295 no DAC has a half-life of approximately 6–8 days, allowing it to extend pulse duration without creating sustained elevated GH levels that would trigger negative feedback suppression of endogenous production. Ipamorelin, with a half-life of roughly 2 hours, provides acute pulse amplitude enhancement when timed strategically—typically before sleep or post-training when the body is already primed for GH secretion. This article covers the exact mechanisms driving fat oxidation and lean mass preservation, the dosing frameworks supported by clinical observation, the storage and reconstitution protocols that preserve peptide integrity, and the specific scenarios where this combination outperforms alternatives.

The Dual-Pathway Mechanism Driving Metabolic Outcomes

CJC-1295 no DAC & Ipamorelin for body recomposition works through two distinct but complementary receptor pathways that together produce GH secretion patterns supporting both lipolysis and protein synthesis. CJC-1295 no DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), modified with a drug affinity complex (DAC removed in the "no DAC" formulation) that extends its half-life while maintaining selectivity for GHRH receptors on anterior pituitary somatotroph cells. When CJC-1295 no DAC binds these receptors, it triggers intracellular cAMP signaling cascades that result in GH gene transcription and secretion—but unlike continuous GHRH infusion, the pulsatile administration pattern prevents receptor desensitization and preserves the body's natural feedback loops.

Ipamorelin operates through a completely different mechanism. It's a pentapeptide ghrelin mimetic that selectively binds to ghrelin receptors (growth hormone secretagogue receptors, or GHS-R1a) on the same pituitary somatotroph cells, but triggers GH release through phospholipase C and calcium-dependent pathways rather than cAMP. The selectivity is what distinguishes Ipamorelin from earlier secretagogues like GHRP-2 or GHRP-6—Ipamorelin produces GH release with minimal effect on cortisol or prolactin, hormones that would counteract body recomposition goals by promoting catabolism and water retention respectively.

The metabolic outcomes driving body recomposition emerge downstream of elevated GH secretion. Growth hormone binds to GH receptors on hepatocytes, triggering IGF-1 (insulin-like growth factor 1) synthesis and secretion—IGF-1 is the primary mediator of GH's anabolic effects on skeletal muscle. Simultaneously, GH exerts direct lipolytic effects on adipocytes by activating hormone-sensitive lipase (HSL), the enzyme responsible for breaking down stored triglycerides into free fatty acids and glycerol for oxidation. Research published in the American Journal of Physiology demonstrated that GH administration increased whole-body fat oxidation by 30–50% while simultaneously increasing nitrogen retention, the hallmark of protein synthesis exceeding breakdown.

The reason the combination matters more than either peptide alone: GHRH analogs like CJC-1295 no DAC extend the duration of each GH pulse but produce relatively modest amplitude increases. Ghrelin mimetics like Ipamorelin create high-amplitude pulses but with short duration due to rapid clearance. Administered together, you get extended high-amplitude pulses—GH secretion that remains elevated for 90–120 minutes rather than 20–30 minutes, creating a metabolic window where lipolysis and protein synthesis occur simultaneously rather than sequentially. This is the hormonal environment where body recomposition becomes possible at the tissue level, not just theoretically.

At Real Peptides, every batch of CJC 1295 NO DAC and Ipamorelin undergoes HPLC verification to confirm >98% purity and exact amino acid sequencing—the structural integrity that determines whether the peptide binds to its target receptor or degrades into inactive fragments. We've seen research teams abandon protocols mid-study because degraded peptides produced inconsistent results that invalidated their data. Purity isn't marketing language; it's the prerequisite for reproducible outcomes.

Dosing Framework, Timing Strategy, and Protocol Duration

The dosing framework for CJC-1295 no DAC & Ipamorelin for body recomposition must account for the distinct pharmacokinetic profiles of each peptide while aligning with the body's natural GH secretion windows. Clinical observation and research protocols typically use CJC-1295 no DAC at 200–300 mcg per injection, administered 2–3 times weekly due to its extended half-life of 6–8 days. This dosing frequency maintains steady GHRH receptor activation without creating the continuous elevation that would trigger negative feedback suppression from elevated somatostatin (the hormone that inhibits GH release).

Ipamorelin dosing ranges from 200–300 mcg per injection, administered once daily, typically 30–45 minutes before sleep or immediately post-training. The rationale: natural GH pulses peak during deep sleep (specifically during slow-wave sleep stages 3 and 4) and again 30–60 minutes post-exercise. Administering Ipamorelin during these windows amplifies endogenous pulses rather than creating artificial peaks at metabolically irrelevant times. A study published in Growth Hormone & IGF Research found that GH secretagogue administration timed to natural pulse windows produced 2.5–3× greater IGF-1 elevation compared to administration at random times throughout the day.

The combination protocol most commonly follows this structure: CJC-1295 no DAC administered subcutaneously at 250 mcg twice weekly (Monday evening, Thursday evening), paired with Ipamorelin at 250 mcg daily before sleep. Total weekly peptide load: 500 mcg CJC-1295 no DAC + 1,750 mcg Ipamorelin. Some protocols substitute a post-training Ipamorelin injection on resistance training days (typically 3–4 days per week) and eliminate the before-bed dose on those days—the goal is to hit 5–7 Ipamorelin injections weekly, always timed to natural GH pulse opportunities.

Protocol duration for body recomposition outcomes typically runs 12–16 weeks minimum. The metabolic adaptations driving fat loss—upregulation of hormone-sensitive lipase in adipocytes, increased mitochondrial density in muscle tissue, shifts in substrate utilization from glucose to fatty acids—require sustained GH elevation over weeks to manifest. Research tracking body composition via DEXA scanning found statistically significant reductions in visceral adipose tissue and increases in lean mass beginning at week 8–10 of GH secretagogue protocols, with continued improvement through week 16. Shorter protocols produce measurable GH elevation but insufficient time for downstream metabolic remodeling.

Reconstitution and storage are non-negotiable for peptide stability. Lyophilized (freeze-dried) CJC-1295 no DAC and Ipamorelin must be stored at −20°C before reconstitution. Once reconstituted with bacteriostatic water, store at 2–8°C (standard refrigerator temperature) and use within 28 days—peptides are proteins, and protein degradation accelerates at room temperature. A single temperature excursion above 25°C for more than 2 hours can denature peptide structure, rendering it inactive without any visible change in appearance. We've worked with labs that lost entire study cohorts because peptides were stored improperly during shipping.

Real Peptides provides CJC1295 Ipamorelin 5MG 5MG as a pre-measured combination for researchers following standardized protocols—eliminating the dosing calculation errors that compromise data integrity. Our small-batch synthesis model means every vial can be traced to its production date, amino acid sequencing run, and purity verification report.

CJC-1295 no DAC & Ipamorelin for Body Recomposition: Peptide Comparison

Understanding how CJC-1295 no DAC & Ipamorelin for body recomposition compares to alternative growth hormone protocols clarifies when this combination is the appropriate research tool versus when other compounds better serve specific endpoints.

| Peptide/Protocol | Mechanism of Action | GH Secretion Pattern | Half-Life | Cortisol/Prolactin Elevation | Body Recomposition Suitability | Professional Assessment ||—|—|—|—|—|—|| CJC-1295 no DAC + Ipamorelin | Dual pathway: GHRH receptor + ghrelin receptor activation | Extended high-amplitude pulses (90–120 min duration) | CJC: 6–8 days; Ipa: 2 hours | Minimal—Ipamorelin is selective | High—synergistic lipolysis + protein synthesis | Best risk-benefit ratio for prolonged body recomposition protocols; mimics natural pulsatility || CJC-1295 with DAC + GHRP-6 | GHRH analog + non-selective ghrelin mimetic | Sustained elevation with high-amplitude spikes | CJC-DAC: 8+ days; GHRP-6: 2 hours | Moderate—GHRP-6 elevates cortisol and prolactin | Moderate—anabolic effects offset by catabolic cortisol | Higher GH output but cortisol elevation compromises fat loss; better for pure mass gain || MK 677 (Ibutamoren) oral | Oral ghrelin mimetic (non-peptide) | Sustained elevation (no pulsatility) | 24 hours | Moderate—elevates cortisol dose-dependently | Moderate—increases appetite significantly | Convenient oral administration but continuous GH elevation may desensitize receptors; appetite increase counterproductive for body recomposition || Exogenous GH (recombinant human growth hormone) | Direct GH receptor agonism—bypasses endogenous secretion | Pharmacological sustained elevation | 2–3 hours in circulation | None directly, but suppresses endogenous production | High—direct receptor activation | Most potent but completely shuts down endogenous GH; expensive; requires precise dosing to avoid side effects || Sermorelin alone | GHRH analog—stimulates pituitary GH release | Moderate-amplitude pulses of moderate duration | 10–20 minutes (very short) | None | Low-Moderate—requires multiple daily dosing for sustained effect | Shortest half-life limits practical application; better as diagnostic tool than recomposition protocol || Tesamorelin + Ipamorelin | GHRH analog (FDA-approved for lipodystrophy) + selective secretagogue | Extended pulses with selective amplitude increase | Tesa: 26–38 min; Ipa: 2 hours | Minimal | High—clinically validated for visceral fat reduction | Similar mechanism to CJC/Ipa but Tesamorelin's shorter half-life requires daily dosing; see Tesamorelin Ipamorelin Growth Hormone Stack |

The bottom line: CJC-1295 no DAC & Ipamorelin for body recomposition offers the best balance of efficacy, safety, and practicality for sustained metabolic remodeling. It preserves endogenous GH production (critical for long-term hormonal health), avoids the appetite surge that sabotages caloric deficits, and requires only 3–4 injections weekly rather than daily administration.

Key Takeaways

CJC-1295 no DAC extends GH pulse duration through GHRH receptor activation with a half-life of 6–8 days, while Ipamorelin amplifies pulse magnitude via selective ghrelin receptor binding—together they produce GH secretion patterns that support simultaneous lipolysis and protein synthesis.

Typical dosing protocols use 200–300 mcg CJC-1295 no DAC twice weekly paired with 200–300 mcg Ipamorelin daily before sleep or post-training, timed to natural GH pulse windows for maximum synergy.

Body recomposition outcomes—measurable fat mass reduction with lean mass preservation—typically emerge after 8–10 weeks of sustained protocol adherence, with continued improvement through 16 weeks as metabolic adaptations solidify.

Lyophilized peptides must be stored at −20°C before reconstitution; once mixed with bacteriostatic water, refrigerate at 2–8°C and use within 28 days to prevent protein degradation that renders peptides inactive.

The CJC-1295 no DAC & Ipamorelin combination avoids cortisol and prolactin elevation seen with non-selective secretagogues, making it suitable for protocols where catabolic hormones would counteract recomposition goals.

Research published in Growth Hormone & IGF Research showed that GH secretagogue administration timed to endogenous pulse windows (sleep, post-exercise) produces 2.5–3× greater IGF-1 response compared to random timing throughout the day.

What If: CJC-1295 no DAC & Ipamorelin Body Recomposition Scenarios

What If I'm Already Running a Caloric Deficit—Will This Combination Prevent Muscle Loss?

Administer the standard protocol (CJC-1295 no DAC 250 mcg twice weekly + Ipamorelin 250 mcg daily before sleep) while maintaining protein intake at 1.6–2.2 g/kg body weight. Growth hormone's primary muscle-preserving effect during caloric restriction is mediated through IGF-1-stimulated protein synthesis and direct inhibition of muscle protein breakdown via mTOR pathway activation. A study in the Journal of Clinical Endocrinology tracked lean mass retention in caloric-restricted subjects receiving GH secretagogues versus placebo—the GH group lost 85% less lean tissue over 12 weeks despite identical caloric deficits. The peptides don't override thermodynamics (you still need adequate protein substrate for synthesis), but they shift the body's fuel preference toward fat oxidation while actively defending muscle tissue through hormonal signaling.

What If I Miss Several Doses Due to Travel—Does the Protocol Reset?

Resume your normal schedule immediately without attempting to "catch up" with double doses. CJC-1295 no DAC's extended half-life means missing one or even two doses reduces but doesn't eliminate GHRH receptor stimulation—plasma concentrations decline gradually over 6–8 days, not precipitously within 24 hours. Missing Ipamorelin doses for 3–5 days interrupts the acute GH pulse amplification but doesn't require a washout or restart. The metabolic adaptations driving body recomposition (upregulated lipolytic enzymes, increased mitochondrial density, improved insulin sensitivity in muscle tissue) develop over weeks and persist for 2–3 weeks even without continued peptide administration. Resume your protocol where you left off; if you've missed more than 10 consecutive days, consider extending your total protocol duration by the number of missed days to achieve the full 12–16 week exposure window.

What If My Scale Weight Isn't Changing Despite Protocol Adherence?

Measure body composition through DEXA, BIA, or at minimum circumference measurements and progress photos—scale weight is the least informative metric for body recomposition. The entire point of CJC-1295 no DAC & Ipamorelin for body recomposition is simultaneous fat loss and lean tissue preservation or gain, which can produce zero net change in total body weight while dramatically altering body composition. Research tracking GH secretagogue protocols via DEXA found that 40% of subjects with statistically significant fat mass reduction (>2 kg) and lean mass gain (>1 kg) showed less than 1 kg change in total scale weight. If circumference measurements (waist, hips, thighs) are decreasing and strength or muscle fullness is maintained or improving, the protocol is working exactly as intended—the scale doesn't capture tissue-level remodeling.

What If I Experience Joint Discomfort or Mild Edema in Hands or Feet?

Reduce Ipamorelin dose to 150–200 mcg daily and assess tolerance over 7–10 days. Mild fluid retention and joint discomfort are known effects of elevated GH and IGF-1—GH increases sodium and water retention through direct effects on the kidney, and IGF-1 stimulates synovial fluid production in joints. These effects are typically transient and resolve as the body adapts to elevated GH levels over 2–4 weeks. If symptoms persist or worsen, discontinue Ipamorelin for 5–7 days (continue CJC-1295 no DAC) and reintroduce at the lower dose. Persistent severe edema or joint pain warrants protocol cessation and consultation with a supervising physician—these can indicate excessive GH elevation beyond the therapeutic window.

The Honest Truth About CJC-1295 no DAC & Ipamorelin for Body Recomposition

Here's the honest answer: CJC-1295 no DAC & Ipamorelin for body recomposition isn't a shortcut around training or nutrition—it's a biological amplifier that makes those inputs more efficient at driving the specific tissue-level changes that define recomposition. If you're not training with sufficient volume and intensity to stimulate muscle protein synthesis, the elevated IGF-1 has no signal to amplify. If you're not consuming adequate protein (1.6–2.2 g/kg minimum), the anabolic hormonal environment can't overcome substrate limitation. And if your caloric deficit is so severe that it triggers adaptive thermogenesis and thyroid downregulation, no peptide protocol will override the hormonal cascade driving metabolic slowdown.

What this combination does—and does uniquely well—is shift fuel partitioning toward fat oxidation while simultaneously defending or building lean tissue, provided the training stimulus and nutritional framework support those outcomes. The dual-pathway GH secretion it produces creates a hormonal environment where lipolysis and protein synthesis occur in the same metabolic window rather than competing for resources. That's mechanistically different from cutting calories alone (which triggers muscle catabolism alongside fat loss) or bulking with excess calories (which builds muscle alongside fat gain). Body recomposition—true simultaneous fat loss and muscle preservation or gain—requires a specific hormonal context that most protocols don't create. This one does.

The limitation: it works within a relatively narrow physiological range. You can't recompose from 25% body fat to 10% in 12 weeks with peptides alone, and you can't build 5 kg of muscle while losing 5 kg of fat unless you're untrained or returning from a long layoff. Realistic outcomes from a 12–16 week protocol: 2–4 kg fat mass reduction with 0.5–1.5 kg lean mass gain in trained individuals, or maintained lean mass with 3–6 kg fat loss in those prioritizing fat reduction. Those numbers don't sell well in marketing copy, but they're what the research and clinical observation support—and they represent meaningful body composition change that diet or training alone struggle to produce simultaneously.

If your research involves metabolic remodeling, lipid oxidation pathways, or anabolic signaling in the context of caloric restriction, the precision and traceability of your peptide source isn't optional. Real Peptides' commitment to small-batch synthesis with complete amino acid sequencing verification means every CJC 1295 NO DAC and Ipamorelin vial produces reproducible receptor binding—the prerequisite for data you can publish. Explore our full peptide collection to see how our manufacturing standards apply across growth factors, neuropeptides, and metabolic modulators.

The peptide combination works. It requires discipline, patience, and a willingness to measure outcomes through body composition rather than scale weight. For researchers studying the hormonal determinants of body recomposition or clinicians exploring metabolic interventions beyond caloric restriction alone, CJC-1295 no DAC & Ipamorelin represents the most practical dual-secretagogue protocol with documented synergistic mechanisms. The question isn't whether it can drive simultaneous fat loss and lean tissue preservation—research confirms it can. The question is whether your protocol design, measurement tools, and patience align with the 12–16 week timeline those outcomes require.

Frequently Asked Questions

CJC-1295 no DAC binds to GHRH receptors on pituitary somatotroph cells, triggering cAMP-mediated GH gene transcription and extending pulse duration through its 6–8 day half-life. Ipamorelin activates ghrelin receptors on the same cells through phospholipase C and calcium-dependent pathways, amplifying GH pulse magnitude without elevating cortisol or prolactin. Together they produce extended high-amplitude GH pulses lasting 90–120 minutes rather than the 20–30 minutes typical of single-peptide protocols. Downstream, elevated GH binds hepatocyte receptors to stimulate IGF-1 synthesis (driving muscle protein synthesis) while directly activating hormone-sensitive lipase in adipocytes to break down stored triglycerides for oxidation—creating the simultaneous anabolic and lipolytic environment that defines body recomposition.

Yes, with careful consideration of mechanism overlap and total hormonal load. CJC-1295 no DAC & Ipamorelin stack well with non-GH-pathway peptides like BPC-157 (tissue repair), TB-500 (muscle recovery), or GHK-Cu (collagen synthesis) because they operate through distinct receptor systems without competitive binding or overlapping side effect profiles. Avoid combining with other GH secretagogues (MK-677, GHRP-2, GHRP-6, Hexarelin) or exogenous GH—stacking GH-stimulating compounds creates excessive GH elevation that triggers negative feedback suppression of endogenous production and increases risk of insulin resistance, joint pain, and edema. If your research requires multiple peptides, space GH-pathway interventions separately in time rather than running them concurrently.

Pharmaceutical-grade recombinant human growth hormone (brands like Norditropin, Humatrope, Genotropin) costs approximately $800–$1,500 per month at therapeutic doses (2–4 IU daily). A CJC-1295 no DAC & Ipamorelin protocol—250 mcg CJC twice weekly plus 250 mcg Ipamorelin daily—typically costs $180–$320 per month depending on supplier and purity grade. The cost differential reflects manufacturing complexity (recombinant protein production in mammalian cell lines versus peptide synthesis) and the regulatory pathway (FDA-approved drug versus research compound). The trade-off: exogenous GH produces higher absolute GH levels but completely suppresses endogenous production, while secretagogue combinations preserve natural pulsatility and hypothalamic-pituitary feedback loops at lower cost.

The most common adverse effects are mild and transient: injection site reactions (redness, swelling), temporary fluid retention causing mild edema in hands or feet, and joint discomfort from increased synovial fluid production driven by elevated IGF-1. These typically resolve within 2–4 weeks as the body adapts to higher GH levels. Less common but documented: transient insulin resistance (GH antagonizes insulin signaling), increased fasting glucose (monitor if diabetic or pre-diabetic), and headaches during dose escalation. Serious adverse events are rare but include potential proliferative effects on existing tumors (GH and IGF-1 are mitogenic—contraindicated in active cancer), worsening of diabetic retinopathy, and carpal tunnel syndrome from prolonged use at high doses. Ipamorelin’s selectivity eliminates the cortisol and prolactin elevation seen with earlier secretagogues, reducing catabolic and water retention risks.

Tesamorelin is an FDA-approved GHRH analog specifically indicated for reducing excess abdominal fat in HIV-associated lipodystrophy—clinical trials showed 15–18% visceral adipose tissue reduction over 26 weeks. Its mechanism is nearly identical to CJC-1295 no DAC (both are GHRH analogs stimulating pituitary GH release), but Tesamorelin has a much shorter half-life (26–38 minutes versus 6–8 days), requiring daily subcutaneous injection. When paired with Ipamorelin, both combinations produce similar GH secretion patterns and body composition outcomes. The practical difference: CJC-1295 no DAC requires only 2–3 injections weekly versus daily Tesamorelin dosing, making it more convenient for long-term protocols. Tesamorelin has more published clinical data specifically for visceral fat, while CJC-1295 no DAC appears more frequently in body recomposition research contexts. Efficacy is comparable; choose based on injection frequency preference and regulatory context.

Metabolic adaptations driving body recomposition—upregulated lipolytic enzymes, increased mitochondrial density, improved insulin sensitivity—persist for 3–6 weeks after protocol cessation before gradually reverting toward baseline. Lean mass gains are more durable than fat loss: muscle tissue built during the protocol remains as long as training stimulus and protein intake are maintained, but the enhanced fat oxidation driven by elevated GH declines within 2–3 weeks of stopping peptides. Research tracking post-protocol outcomes found that subjects who transitioned to maintenance calories and continued resistance training retained 70–85% of lean mass gains and approximately 60% of fat mass reduction at 12 weeks post-cessation. To maximize retention, taper peptide doses over 2–4 weeks rather than stopping abruptly, allowing endogenous GH production to resume gradually without the rebound suppression that can follow sudden cessation of exogenous hormonal interventions.

Yes, women respond to GH secretagogue protocols with outcomes comparable to men, though baseline GH secretion patterns differ by sex—women naturally produce more GH in a pulsatile pattern with higher pulse frequency but lower amplitude. This means women may experience slightly greater relative GH elevation from secretagogue protocols, but estrogen’s synergistic effects on GH receptor sensitivity and IGF-1 production create similar net anabolic and lipolytic outcomes. Dosing protocols do not require sex-based adjustment; the standard 200–300 mcg CJC-1295 no DAC twice weekly plus 200–300 mcg Ipamorelin daily applies equally. Women should monitor for fluid retention more closely during luteal phase (days 15–28 of menstrual cycle) when progesterone naturally increases water retention—this can compound mild GH-induced edema. Contraindicated during pregnancy and breastfeeding due to unknown effects on fetal development and potential transfer through breast milk.

A washout period of 4–6 weeks between 12–16 week protocols allows hypothalamic-pituitary-somatotroph axis recovery and prevents receptor desensitization from prolonged elevated GH signaling. During this washout, endogenous GH secretion returns to baseline (typically within 2–3 weeks based on half-life clearance), somatostatin tone normalizes, and GHRH and ghrelin receptor sensitivity resets. Running continuous protocols beyond 16 weeks without breaks risks diminishing returns as the body adapts to chronic GH elevation through compensatory mechanisms—increased somatostatin release, receptor downregulation, and hepatic IGF-1 resistance. Some research protocols use a ‘time on equals time off’ rule: a 12-week protocol followed by 12 weeks off before repeating. If body composition goals haven’t been met after one cycle, the washout period allows assessment of which adaptations are durable and informs adjustments to training or nutrition variables before beginning the next peptide intervention.

The DAC (Drug Affinity Complex) is a chemical modification that extends CJC-1295’s half-life from approximately 30 minutes to 8+ days by binding to serum albumin and preventing rapid enzymatic degradation. CJC-1295 with DAC creates sustained GH elevation for days after a single injection—convenient for dosing but problematic for mimicking natural pulsatility. The ‘no DAC’ version retains a shorter half-life (6–8 days versus 8+ days) that allows more physiological pulsatile GH release when dosed 2–3 times weekly rather than continuous elevation. For body recomposition, pulsatile GH patterns are superior to sustained elevation—research shows that continuous GH exposure triggers faster receptor desensitization and stronger negative feedback (elevated somatostatin) that blunts the anabolic and lipolytic response over time. CJC-1295 no DAC preserves the body’s natural feedback loops and pulse architecture, making it the preferred form for protocols lasting longer than 8 weeks.

No, both peptides should be stopped simultaneously at protocol end. Because they work through complementary pathways to produce the synergistic GH secretion pattern driving body recomposition outcomes, discontinuing one while continuing the other eliminates half the mechanism and produces GH secretion that reverts to single-pathway stimulation—less effective than the combination and not meaningfully different from baseline. Ipamorelin’s 2-hour half-life means it clears from circulation within 8–12 hours of the last injection, while CJC-1295 no DAC takes 6–8 days for full clearance. This staggered pharmacokinetic timeline is intentional and beneficial—it allows GH secretion to taper gradually rather than dropping precipitously, reducing the hormonal shock that can trigger rebound fat gain or muscle catabolism. Stop both peptides on the same day and allow the natural clearance timeline to create a physiological taper.